Am. J. Respir. Crit. Care Med., Volume 157, Number 2, February 1998, 565-573

Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast Cancer

STEPHEN W. WILCZYNSKI, JEREMY J. ERASMUS, WILLIAM P. PETROS, JAMES J. VREDENBURGH, and RODNEY J. FOLZ

Departments of Medicine, Radiology, and Cell Biology, Duke University Medical Center, Durham, North Carolina

We have intensely followed 45 consecutive women who underwent high-dose chemotherapy (cyclophosphamide/cisplatin/BCNU) and autologous bone marrow transplant (HDC/ABMT) for primary breast cancer with pulmonary function testing and computed tomography at regular intervals up to 126 wk (median follow-up, 72 wk). Our results show a high incidence of interstitial pneumonitis requiring steroids (64%), but no deaths due to pulmonary toxicity. The DL_CO reaches a nadir of 58.2 ± SEM 3.4 (expressed as a percent of baseline value) 15-18 wk following HDC/ABMT, and marginally improves with time. To a much lesser extent, vital capacity is reduced with a parallel drop in FEV₁, suggesting mild restrictive changes without significant obstruction. Patients who develop pulmonary symptoms of cough or dyspnea have a corresponding significantly greater and earlier decline in DL_CO. Chest computed tomography was neither sensitive nor specific for diagnosing pulmonary toxicity. For patients who received steroids for pulmonary toxicity, there was a subsequent improvement in DL_CO of 17.1% (p = 0.0001). Because our patients do not fit with the recent definition of idiopathic pulmonary syndrome (IPS), we propose the term delayed pulmonary toxicity syndrome (DPTS) to better describe the milder form of lung toxicity seen in our patient population. We were unable to correlate the severity of DPTS with age, tobacco use, baseline pulmonary function, or systemic exposure to BCNU, cyclophosphamide, or cisplatin. These data suggest that factor(s) other than, or in addition to, chemotherapy systemic exposure can contribute to DPTS. Furthermore, early identification and institution of systemic corticosteroids may improve lung function.

This article has been cited by other articles:

				K. S. Bhalla and R. J. Folz Idiopathic Pneumonia Syndrome after Syngeneic Bone Marrow Transplant in Mice Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1579 - 1589. [Abstract] [Full Text] [PDF]

				A. M. Abushamaa, T. A. Sporn, and R. J. Folz Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L336 - L345. [Abstract] [Full Text] [PDF]

				W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705. [Abstract] [Full Text] [PDF]

				A T Whittle, M Davis, C L Shovlin, P S Ganly, C Haslett, and A P Greening Alveolar macrophage activity and the pulmonary complications of haematopoietic stem cell transplantation Thorax, December 1, 2001; 56(12): 941 - 946. [Abstract] [Full Text] [PDF]

				K. S. BHALLA, S. W. WILCZYNSKI, A. M. ABUSHAMAA, W. P. PETROS, C. S. MCDONALD, J. S. LOFTIS, N. J. CHAO, J. J. VREDENBURGH, and R. J. FOLZ Pulmonary Toxicity of Induction Chemotherapy Prior to Standard or High-dose Chemotherapy with Autologous Hematopoietic Support Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 17 - 25. [Abstract] [Full Text]

				R. J. Folz Mechanisms of Lung Injury after Bone Marrow Transplantation Am. J. Respir. Cell Mol. Biol., June 1, 1999; 20(6): 1097 - 1099. [Full Text]

				R. J. Folz and M. A. Elkordy Coronavirus Pneumonia Following Autologous Bone Marrow Transplantation for Breast Cancer Chest, March 1, 1999; 115(3): 901 - 905. [Abstract] [Full Text] [PDF]